See more : AB Sagax (publ) (0QDX.IL) Income Statement Analysis – Financial Results
Complete financial analysis of Cipher Pharmaceuticals Inc. (CPH.TO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cipher Pharmaceuticals Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Inalways Corporation (5398.TWO) Income Statement Analysis – Financial Results
- SCHMID Group N.V. Class A Ordinary Shares (SHMD) Income Statement Analysis – Financial Results
- Sinomach Precision Industry Co.,Ltd. (002046.SZ) Income Statement Analysis – Financial Results
- Terna Energy Societe Anonyme Commercial Technical Company (TREAF) Income Statement Analysis – Financial Results
- Renascor Resources Limited (RNU.AX) Income Statement Analysis – Financial Results
Cipher Pharmaceuticals Inc. (CPH.TO)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.cipherpharma.com
About Cipher Pharmaceuticals Inc.
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. Its commercial products include Epuris (CIP-ISOTRETINOIN), a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; Ozenoxacin to treat adult and paediatric patients with impetigo; Actikerall, which is indicated for the treatment of palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a prescription cream that reduces the growth of unwanted facial hair in women; BRINAVESS, a treatment for sinus rhythm in adults; and AGGRASTAT, an intravenous anti-platelet drug. The company's licensed products comprise CIP-Isotretinoin; Lipofen (CIP-Fenofibrate), a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; and Conzip/Durela (CIP- Tramadol), a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain. Its pipeline products include Trevyent, a vasodilatory prostacyclin analogue to treat pulmonary arterial hypertension; CF-101 for severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical formulation of terbinafine for the treatment of onychomycosis; and DTR-001, a tattoo removal cream. Cipher Pharmaceuticals Inc. was founded in 2000 and is headquartered in Oakville, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 21.16M | 20.68M | 21.94M | 21.61M | 22.45M | 22.75M | 40.32M | 40.74M | 34.41M | 8.26M | 25.37M | 8.50M | 3.50M | 5.38M | 3.04M | 1.27M | 543.27K | 779.00K | 646.63K | 25.42M |
| Cost of Revenue | 4.07M | 3.99M | 3.68M | 3.06M | 2.91M | 2.31M | 1.90M | 4.59M | 2.53M | 1.03M | 133.36K | 1.52M | 0.00 | 0.00 | 0.00 | 0.00 | 172.67K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 17.09M | 16.68M | 18.26M | 18.55M | 19.55M | 20.44M | 38.42M | 36.15M | 31.88M | 7.23M | 25.23M | 6.98M | 3.50M | 5.38M | 3.04M | 1.27M | 370.60K | 779.00K | 646.63K | 25.42M |
| Gross Profit Ratio | 80.77% | 80.69% | 83.21% | 85.85% | 87.06% | 89.84% | 95.28% | 88.74% | 92.66% | 87.53% | 99.47% | 82.10% | 100.00% | 100.00% | 100.00% | 100.00% | 68.22% | 100.00% | 100.00% | 100.00% |
| Research & Development | 440.00K | 98.00K | 88.00K | 129.00K | 396.00K | 561.00K | 394.00K | 561.00K | 2.14M | 1.06M | 1.30M | 1.52M | 2.16M | 742.88K | 913.00K | 1.07M | 2.29M | 7.26M | 12.13M | 10.36M |
| General & Administrative | 5.39M | 4.40M | 0.00 | 0.00 | 0.00 | 14.74M | 12.78M | 23.74M | 16.59M | 5.68M | 5.84M | 3.55M | 3.12M | 3.89M | 4.06M | 2.93M | 4.89M | 3.44M | 2.70M | 23.30M |
| Selling & Marketing | 0.00 | 1.14M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 14.46M | 8.81M | 1.83M | 1.93M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 5.39M | 5.54M | 5.11M | 6.26M | 7.65M | 14.74M | 12.78M | 38.20M | 25.41M | 7.51M | 5.84M | 3.55M | 3.12M | 3.89M | 4.06M | 2.93M | 4.89M | 3.44M | 2.70M | 23.30M |
| Other Expenses | 0.00 | 0.00 | 1.25M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.40M | 652.96K | 1.04M | 1.03M | 566.11K | 756.88K | 773.57K | 441.25K | 521.05K | 419.53K | 16.36K | -2.23M |
| Operating Expenses | 5.56M | 5.63M | 6.45M | 6.39M | 8.04M | 15.30M | 13.18M | 38.76M | 31.95M | 12.06M | 8.18M | 6.10M | 5.85M | 5.39M | 5.75M | 4.44M | 7.70M | 11.13M | 14.85M | 31.43M |
| Cost & Expenses | 9.63M | 9.63M | 10.13M | 9.44M | 10.95M | 17.61M | 15.08M | 43.35M | 34.48M | 13.09M | 8.31M | 6.10M | 5.85M | 5.39M | 5.75M | 4.44M | 7.87M | 11.13M | 14.85M | 31.43M |
| Interest Income | 1.87M | 464.00K | 12.00K | 32.00K | 179.00K | 195.00K | 8.00K | 54.00K | 371.00K | 1.58K | 237.61K | 155.81K | 87.17K | 65.99K | 118.42K | 374.69K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 464.00K | 92.00K | 323.00K | 965.00K | 907.00K | 5.30M | 7.78M | 3.82M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 476.65K |
| Depreciation & Amortization | 1.23M | 989.00K | 701.00K | 1.21M | 1.19M | 828.00K | 967.00K | 5.73M | 4.47M | 1.30M | 1.06M | 1.05M | 602.35K | 756.88K | 773.57K | 441.25K | 521.05K | 419.53K | 16.36K | 809.39K |
| EBITDA | 11.26M | 11.95M | 13.66M | 13.40M | 12.87M | 6.16M | 26.03M | 12.66M | 7.19M | 17.71M | 18.11M | 3.45M | -1.75M | 862.86K | -1.94M | -2.73M | -6.81M | -9.93M | -14.18M | -5.20M |
| EBITDA Ratio | 53.21% | 58.40% | 57.07% | 62.02% | 57.32% | 27.07% | 65.02% | 10.67% | 13.86% | -42.70% | 71.39% | 40.60% | -50.01% | 13.87% | -63.83% | -215.49% | -1,253.16% | -1,274.67% | -2,193.48% | -20.46% |
| Operating Income | 11.53M | 11.09M | 11.82M | 12.20M | 11.68M | 5.33M | 25.24M | -31.83M | -68.00K | -4.83M | 17.05M | 2.40M | -2.35M | -10.00K | -2.71M | -3.17M | -7.33M | -10.35M | -14.20M | -6.01M |
| Operating Income Ratio | 54.48% | 53.62% | 53.87% | 56.44% | 52.03% | 23.43% | 62.60% | -78.13% | -0.20% | -58.44% | 67.22% | 28.25% | -67.25% | -0.19% | -89.30% | -250.29% | -1,349.07% | -1,328.53% | -2,196.01% | -23.65% |
| Total Other Income/Expenses | 1.15M | -560.00K | -2.00M | -5.63M | -5.79M | -2.01M | -11.15M | -5.83M | -2.89M | 465.17K | 237.61K | 155.81K | 87.17K | 65.99K | 0.00 | 144.62K | 0.00 | 0.00 | -139.49K | -476.65K |
| Income Before Tax | 12.68M | 11.48M | 11.06M | 6.54M | 5.71M | 3.12M | 14.27M | -37.66M | -1.15M | -4.82M | 17.29M | 2.56M | -2.26M | 0.00 | 0.00 | -3.03M | 0.00 | -10.35M | -14.34M | -6.49M |
| Income Before Tax Ratio | 59.92% | 55.52% | 50.40% | 30.25% | 25.43% | 13.73% | 35.38% | -92.43% | -3.33% | -58.42% | 68.16% | 30.08% | -64.75% | 0.00% | 0.00% | -238.89% | 0.00% | -1,328.53% | -2,217.58% | -25.52% |
| Income Tax Expense | -7.70M | -15.16M | 3.30M | 2.15M | 3.07M | 1.92M | 3.52M | 1.49M | -2.92M | -284.27K | -6.16M | -155.81K | -87.17K | -65.99K | -118.42K | -519.31K | -820.96K | 0.42 | 81.80K | 3.44M |
| Net Income | 20.38M | 26.64M | 7.76M | 4.55M | 3.24M | 543.00K | 4.40M | -39.15M | 1.77M | -4.82M | 23.45M | 2.56M | -2.26M | 55.99K | -2.59M | -2.65M | -6.51M | -10.35M | -7.32M | -9.93M |
| Net Income Ratio | 96.32% | 128.83% | 35.36% | 21.05% | 14.44% | 2.39% | 10.92% | -96.09% | 5.14% | -58.42% | 92.43% | 30.08% | -64.75% | 1.04% | -85.40% | -209.33% | -1,197.96% | -1,328.53% | -1,132.76% | -39.08% |
| EPS | 0.80 | 0.25 | 0.29 | 0.17 | 0.12 | 0.02 | 0.16 | -1.49 | 0.07 | -0.19 | 0.96 | 0.10 | -0.09 | 0.00 | -0.11 | -0.11 | -0.27 | -0.44 | -0.34 | -0.47 |
| EPS Diluted | 0.80 | 0.25 | 0.29 | 0.17 | 0.12 | 0.02 | 0.16 | -1.45 | 0.07 | -0.19 | 0.91 | 0.10 | -0.09 | 0.00 | -0.11 | -0.11 | -0.27 | -0.44 | -0.34 | -0.47 |
| Weighted Avg Shares Out | 25.48M | 107.49M | 26.60M | 27.03M | 26.85M | 26.77M | 26.57M | 26.20M | 25.94M | 25.67M | 24.56M | 24.38M | 24.18M | 24.07M | 24.05M | 24.05M | 24.05M | 23.65M | 21.27M | 20.95M |
| Weighted Avg Shares Out (Dil) | 25.42M | 107.49M | 26.83M | 27.37M | 26.96M | 27.00M | 26.77M | 27.06M | 26.38M | 25.67M | 25.74M | 24.67M | 24.18M | 24.07M | 24.05M | 24.05M | 24.05M | 23.65M | 21.27M | 20.95M |
Source: https://incomestatements.info
Category: Stock Reports